Brodalumab in psoriasis: evidence to date and clinical potential

Article Page


Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to market in the class of agents targeting IL-17, we review its place in the expanding armamentarium of cytokine-directed therapies for patients with severe psoriasis. Brodalumab is a highly efficacious therapy for psoriasis, whose mechanism of action is separate from other treatments targeting IL-17. Its use is associated with rapid control of the disease. We suggest that brodalumab is likely to be considered in those patients requiring rapid control of disease, where there is no known history of depression or suicidal ideation.

Keywords: immune-mediated inflammatory disease, psoriasis, psoriatic arthritis.

Citation: Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs in Context 2019; 8: 212570. DOI: 10.7573/dic.212570

Contributions: The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: Dr AC Foulkes has received educational support to attend conferences from or acted as a consultant or speaker for Abbvie, Almirall, Celgene, Eli Lilly, Leo Pharma, Novartis, Pfizer, Janssen and UCB. Professor RB Warren has acted as a consultant and/or speaker for Abbvie, Amgen, Almirall, Boehringer, Medac, Eli Lilly, Janssen, Leo Pharma, Pfizer, Novartis, Sun Pharma, Valeant, Schering-Plough (now MSD) and Xenoport. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2019 Foulkes AC, Warren RB. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Foulkes AC, Warren RB. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL:

Correspondence: Amy C Foulkes, The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester Biomedical Research Centre, M6 8HD, UK.

Provenance: invited; externally peer reviewed.

Submitted: 1 November 2018; Peer review comments to author: 4 December 2018; Revised manuscript received: 22 January 2019; Accepted: 24 January 2019; Publication date: 17 April 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief

For all permissions, rights and reprints, contact David Hughes

Download free full text PDF